Linker, antibody-drug conjugate, and preparation method therefor
Through the design of new linker-antibody conjugates, the problems of insufficient stability and pharmacokinetic properties of ADC were solved, and efficient delivery and drug release of antibody drugs at the tumor site were achieved, thereby enhancing the therapeutic effect.
Patent Information
- Application Number
- PCT/CN2025/086645
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-09-27
- Filing Date
- 2025-04-01
- Publication Date
- 2025-10-09
AI Technical Summary
Existing antibody-drug conjugates (ADCs) have deficiencies in stability and pharmacokinetic properties, resulting in uneven distribution in the body and poor efficacy, especially aggregation and sedimentation caused by traditional linkers and rapid liver metabolism.
A new type of linker, containing a linker group with a specific structure and a glucose group, is used to form an antibody-drug conjugate (ADC) by coupling with an antibody to increase the drug loading capacity and optimize the physicochemical and pharmacokinetic properties of the ADC.
It achieves efficient delivery and drug release of antibody-drug conjugates in tumor target cells, increases drug accumulation at the tumor site, enhances the therapeutic effect, and controls the drug exposure and half-life in plasma.